Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Exocrine Pancreatic Insufficiency Clear all
Completed Phase 3 Interventional Results available

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

NCT02279498
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase, porcine (pig) PERT
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
32
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis

NCT05719311
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
adrulipase
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Orlando, Florida • Northfield, Illinois • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Not applicable Interventional

Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis

NCT04966897
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
GlycosBio Nutritional Supplement + PERT placebo, Standard Nutritional Supplement + PERT
Dietary Supplement
Lead sponsor
GlycosBio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Results available

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

NCT00919503
View directory record Official record
Conditions
Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions
Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation
Procedure · Biological · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

NCT01100606
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
1 Month to 12 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Jacksonville, Florida • Las Vegas, Nevada • Akron, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 2, 2026, 4:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pancreatic Insufficiency Secondary to Tobacco Exposure

NCT01988350
View directory record Official record
Conditions
Pancreatic Insufficiency
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
30 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 2, 2026, 4:26 PM EDT
Recruiting Phase 4 Interventional

Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency

NCT06477159
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
Pancrelipase Capsules
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 2, 2026, 4:26 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Diabetes/ Endocrine Surveillance in SDS

NCT04275479
View directory record Official record
Conditions
Shwachman-Diamond Syndrome
Interventions
Oral Glucose Tolerance Test, Modified Oral Glucose Tolerance Test, Modified Mixed Meal Tolerance Test, Continuous Glucose Monitor, Food Diary, Medical History Questionnaires
Diagnostic Test · Other · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 2, 2026, 4:26 PM EDT
Withdrawn Not applicable Interventional

Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients

NCT00663975
View directory record Official record
Conditions
Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
DCI 1020
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
Up to 2 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Results available

PR-018: An Open-Label, Safety Extension of Study PR-011

NCT01131507
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 12 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Jacksonville, Florida • Las Vegas, Nevada • Akron, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

NCT00513682
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT20
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 2, 2026, 4:26 PM EDT
Recruiting Phase 4 Interventional

Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis

NCT07418593
View directory record Official record
Conditions
Chronic Pancreatitis, Recurrent Acute Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions
Pancreatic Enzyme Replacement Therapy, Placebo, MBT1, MBT 2
Drug · Diagnostic Test
Lead sponsor
Anna Evans Phillips
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Phase 2 Interventional

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

NCT00095732
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Liprotamase, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 2, 2026, 4:26 PM EDT
Terminated Phase 1 Interventional Results available

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

NCT02231710
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
Interventions
BPX-501 and Rimiducid
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
4 Months to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 2, 2026, 4:26 PM EDT
Terminated Not applicable Interventional Results available

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

NCT01319851
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions
Alefacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 2, 2026, 4:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 2, 2026, 4:26 PM EDT
Terminated Not applicable Interventional

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

NCT02179359
View directory record Official record
Conditions
Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
Interventions
Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

NCT00981214
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 7 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 2, 2026, 4:26 PM EDT
Recruiting No phase listed Observational

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

NCT06999954
View directory record Official record
Conditions
Shwachman-Diamond Syndrome, SDS, IBMF, Congenital Neutropenia, Heme Malignancy, Shwachman Syndrome, Inherited Bone Marrow Failure, Exocrine Pancreatic Insufficiency, WHIM, ELANE, SBDS Gene Mutation, EFL1 Gene Mutation, DNAJC21 Gene Mutation, SRP54 Gene Mutation, Inherited Cancer Syndrome, Inherited Cancer-Predisposing Syndrome, Neutropenia, Severe Chronic, Neutropenia Other, Neutropenia Chronic Benign, Ribosome Alteration, Ribosomopathy, Immune Deficiency, Inherited BMF Syndrome, Inherited Immunodeficiency Diseases, Cognitive Delay, Mild, Myelodysplastic Syndromes, Pancytopenia
Interventions
Not listed
Lead sponsor
Shwachman-Diamond Syndrome Alliance Inc
Other
Eligibility
Not listed
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2088
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 2, 2026, 4:26 PM EDT
Terminated Phase 4 Interventional

Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control

NCT00744250
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Cystic Fibrosis
Interventions
Pancrelipase
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Results available

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

NCT00880100
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT12
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Years to 6 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
15
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Grand Rapids, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 2, 2026, 4:26 PM EDT
Completed Phase 2 Interventional

Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI

NCT00406536
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Lym-X-Sorb powder, Placebo powder
Dietary Supplement
Lead sponsor
Avanti Polar Lipids, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 2, 2026, 4:26 PM EDT
Completed No phase listed Observational

Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis

NCT01144507
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Abdominal Ultrasound, Sample collection procedures
Procedure · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 12 Years
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
10
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 2, 2026, 4:26 PM EDT
Recruiting Not applicable Interventional

Nutrition Intervention for Pancreatic Cancer

NCT07554560
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Neuroendocrine Tumor (NET)
Interventions
Structured Lipid Medical Food
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 2, 2026, 4:26 PM EDT